Discover

ATNM
Actinium Pharmaceuticals, Inc.
0.79
2 x 0.63
1 x 0.83
bid
ask
+
0.02
2.41%
01:07 PM
timesize
Ytd-42.00%
1y-46.34%
0.78
day range
0.82
0.73
52 week range
1.81
Open0.78Prev Close0.77Low0.78High0.82Mkt Cap24.75M
Vol142.34KAvg Vol117.48KEPS-0.75P/E-1.05Forward P/E-1.77
Beta0.01Short Ratio5.72Inst. Own30.11%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0850-d Avg0.96200-d Avg1.201yr Est5.00

ATNM News

benzinga.com
Actinium's ATNM-400 Reports Preclinical Activity And Combination Synergy Across KRAS- And EGFR-Mutan

New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib

benzinga.com
Actinium Pharma Presents New Data On ATNM-400 In Prostate Cancer At SNMMI 2026 Annual Meeting

New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant

benzinga.com
Actinium Pharmaceuticals Obtains Two Patent Allowances Spanning Its Actimab-A And Iomab-ACT Programs

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of

benzinga.com
Actinium Pharmaceuticals To Reveal ATNM-400 Program Update At SNMMI 2026 Conference on May 31-June 2

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of

benzinga.com
Actinium Highlights Data Presented At AACR Supporting Transcriptional Reprogramming As Central Mecha

Actimab-A combinations enhanced in vivo AML cell killing across multiple preclinical models, indepen

benzinga.com
Actinium Pharma Presents Preclinical Results For ATNM-400 Across Prostate, Lung, And Breast Cancer M

ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting

benzinga.com
Stephens & Co. Reiterates Overweight on Actinium Pharma, Maintains $5 Price Target

Stephens & Co. analyst Sudan Loganathan reiterates Actinium Pharma (AMEX:ATNM) with a Overwei

benzinga.com
Actinium To Present Abstracts On ATNM-400 And Actimab-A Programs Across Solid Tumors And Hematologic

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic On

benzinga.com
Actinium Pharma Advances Solid-Tumor Program With Phase 1 Clinical Trial In South Africa Targeting B

Actinium Pharmaceuticals (NYSE:ATNM), a company developing targeted alpha radiotherapies, is advanci

benzinga.com
Actinium Pharma To Present Preclinical Data For ATNM-400, Actinium-225 Antibody Radioconjugate, In H

 Presentation to include new data in triple-negative disease, a breast cancer subtype with poor outc

benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  On Tuesday, 647 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Monday

  On Monday, 369 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Friday

  During Friday's session, 445 companies made new 52-week lows.

benzinga.com
62 Biggest Movers From Yesterday

Gainers Universal Security Instruments, Inc. (NYSE: UUU) shares climbed 62.3% to close at $5.00 o

benzinga.com
45 Stocks Moving In Tuesday's Mid-Day Session

Gainers Universal Security Instruments, Inc. (NYSE: UUU) shares jumped 303.2% to $12.42. DPW Hold

benzinga.com
Stocks That Hit 52-Week Highs On Monday

  This morning 180 companies set new 52-week highs.